Drug slows modernized prostate cancer: study

<p>A drug that is already authorized for <span>prostate cancer</span> has been shown to behind a widespread of modernized forms of a illness for a initial time, according to <span>research</span> expelled Saturday.</p>
<p>Zytiga, done by Johnson and Johnson, is being tested in a randomized proviso III hearing involving 1,088 organisation with prostate cancer during 151 <span>cancer</span> comforts in North America, Europe and Australia.</p>
<p>On average, participants in a investigate were diagnosed 5 years before to entering a investigate though nothing had begun chemotherapy.</p>
<p>Their cancer had metastasized and had turn resistant to initial hormone therapy, though they were not display vital symptoms.</p>
<p>According to halt results, a drug, abiraterone acetate, given in multiple with prednisone, behind a conflict of pain and helped urge peculiarity of life in patients whose cancer had met...